Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by NewLink Genetics Corporation
Sponsor:
Information provided by (Responsible Party):
NewLink Genetics Corporation
ClinicalTrials.gov Identifier:
NCT01774578
First received: January 7, 2013
Last updated: July 1, 2014
Last verified: July 2014
  Purpose

The purpose of this study is to assess overall survival of anti-tumor immunization using HyperAcute®-Lung immunotherapy versus Docetaxel in patients with progressed or relapsed non-small cell lung cancer (NSCLC) that have been previously treated.


Condition Intervention Phase
Non-small Cell Lung Cancer
Progression of Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Recurrent
Drug: Docetaxel
Biological: HyperAcute®-Lung Immunotherapy
Drug: Gemcitabine
Drug: Pemetrexed
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Hyper-Acute(R)-Lung (Tergenpumatucel-L) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by NewLink Genetics Corporation:

Primary Outcome Measures:
  • Overall survival [ Time Frame: Approximately 19 months, assuming a 24 month enrollment. ] [ Designated as safety issue: No ]
    The primary objective in Phase IIB and Phase III is to assess overall survival of anti-tumor immunization using HyperAcute®-Lung (HAL) Immunotherapy versus docetaxel in patients with progressed or relapsed non-small cell lung cancer (NSCLC) that have been previously treated.


Secondary Outcome Measures:
  • Dosing schedule [ Time Frame: Approximately 19 months, assuming a 24 month enrollment. ] [ Designated as safety issue: No ]
    A secondary objective in Phase IIB is to determine the response rates of HyperAcute®-Lung (HAL) Immunotherapy given in a weekly and biweekly regimen versus docetaxel.

  • Tumor response rate [ Time Frame: Approximately 19 months, assuming a 24 month enrollment. ] [ Designated as safety issue: No ]
    A secondary outcome measure in Phase IIB and Phase III is to measure tumor response including response to follow-on salvage regimens to assess chemosensitization effects.

  • Immunologic Response [ Time Frame: Approximately 19 months, assuming a 24 month enrollment. ] [ Designated as safety issue: No ]
    A secondary outcome measure in Phase IIB and Phase III is to assess the immunological response of patients with lung cancer treated with HyperAcute®-Lung (HAL) Immunotherapy versus docetaxel in patients with progressed or relapsed NSCLC that have been previously treated.


Estimated Enrollment: 240
Study Start Date: January 2013
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm 1: Docetaxel

Arm 1: Docetaxel 75 mg/m^2 IV given every 3 weeks x 4 doses. If response or stable: Observe until disease progression.

First Progression: Gemcitabine 1250 mg/m^2/week for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity.

Drug: Docetaxel
Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
Other Name: Taxotere®
Drug: Gemcitabine
Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
Other Name: Gemzar®
Drug: Pemetrexed
Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
Other Name: Alimta®
Experimental: Arm 2a: HyperAcute®-Lung Immunotherapy (weekly)

Arm 2a: 300 Million HAL cells given by intradermal injection weekly for 11 weeks and then every 2 months for 5 additional doses.

Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.

First Progression: Docetaxel 75 mg/m^2 IV given every 3 weeks or Gemcitabine 1250 mg/m^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations).

Drug: Docetaxel
Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
Other Name: Taxotere®
Biological: HyperAcute®-Lung Immunotherapy

HAL-1, HAL-2 and HAL-3 immunotherapy components.

Up to 16 immunizations of 300 million immunotherapy cells.

Other Name: Tergenpumatucel-L
Drug: Gemcitabine
Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
Other Name: Gemzar®
Drug: Pemetrexed
Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
Other Name: Alimta®
Experimental: Arm 2b: HyperAcute®-Lung Immunotherapy (biweekly)

Arm 2b: 300 Million HAL cells given by intradermal injection biweekly for 6 doses and then every month for 10 additional doses.

Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.

First Progression: Docetaxel 75 mg/m^2 IV given every 3 weeks or Gemcitabine 1250 mg/m^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations).

Drug: Docetaxel
Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
Other Name: Taxotere®
Biological: HyperAcute®-Lung Immunotherapy

HAL-1, HAL-2 and HAL-3 immunotherapy components.

Up to 16 immunizations of 300 million immunotherapy cells.

Other Name: Tergenpumatucel-L
Drug: Gemcitabine
Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
Other Name: Gemzar®
Drug: Pemetrexed
Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
Other Name: Alimta®

Detailed Description:

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death in men and women in the United States. Despite advances in the treatment of advanced NSCLC in the last decade, survival outcomes remain poor. Treatment benefit from cytotoxic chemotherapy has reached a plateau and further progress will depend upon identifying novel methods to target tumor cells.

Harnessing the human immune system to target lung cancer could result in the development of effective treatment options against lung cancer and potentially enhance the effect of cytotoxic chemotherapy. Lung cancer cells produce a number of abnormal proteins or abnormal amounts of certain proteins found in normal lung cells. In some cancers, the abnormal protein expression may lead to an immune response against the cancer cells much in the way the immune system responds to an infection. In progressive lung cancer however, the immune system fails to identify or respond to these abnormalities and the cancer cells are not attacked or destroyed for reasons not yet fully understood. This clinical trial proposes a novel method to stimulate the immune system to recognize the abnormal components found in lung cancer cells and to stimulate an immune response that destroys or blocks the growth of the cancer.

This new method of treatment helps the immune system of lung cancer patients to "identify" and target the cancerous tissue. As an example, patients who receive an organ transplant to replace a damaged kidney or heart are treated with special drugs to supress their immune response from destroying or "rejecting" the transplanted organ. This "rejection" occurs when the patient's immune system responds to differences between the cells of the transplanted organ and their own immune system by attacking the foreign tissue in the same way as it would attack infected tissue. When the differences between foreign tissues and the patient's body are even larger, perhaps like differences between organs from pigs and the immune system cells of humans, the rejection is very rapid, highly destructive and the immunity it generates is long-lasting. This is called hyperacute rejection and the medicine used to immunize patients in this protocol tries to harness this response to teach a patient's immune system to fight their lung cancer just as the body would learn to reject a transplanted organ from an animal.

To do this, we have placed a mouse gene into cultured human lung cancer cell lines. These cells will express a sugar that will stimulate a strong immune response in humans. These cancer cells are irradiated to prevent any growth and then injected along with chemotherapy to patients with lung cancer. The presence of the sugar will stimulate the patient's immune system to kill the injected immunotherapy cells. As part of the process of destroying the immunotherapy cells, the patient's immune system is stimulated to identify as many differences between these cancer cells and normal human cells. This extra stimulation is thought to encourage immune responses against the lung cancer in the patient based on shared abnormalities of lung cancer immunotherapy cells and the patient's lung cancer cells.

In this experimental therapy, patients are given docetaxel or injections of an immunotherapy consisting of three types of modified lung cancer cells. We propose to test these treatments in patients with lung cancer who have progressed after initial chemotherapy to demonstrate that treatment of immunotherapy results in improved tumor stabilization or response and could potentially improve the patient's overall survival.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological diagnosis of non-small cell lung cancer (NSCLC). Squamous cell (epidermoid), adenocarcinoma, bronchoalveolar carcinoma, and large cell anaplastic lung carcinoma histologies are eligible as are mixed histologies of NSCLC (i.e., adenosquamous). Mixed NSCLC/small cell lung carcinoma (SCLC), and variant large and small cell lung cancer are not eligible.
  • Stage IIIB (AJCC Stage IIIB - Any T,N3M0 or T4N2M0) or Metastatic (AJCC Stage IV- any T, any N, M1), progressive, recurrent or refractory NSCLC. Patients may not be eligible for other curative intent treatment (e.g., surgical resection).

For the purpose of eligibility for this trial, the above-cited disease states are defined as follows:

  • Progressive NSCLC: Defined as increasing measurable disease, or the appearance of new measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria despite treatment.
  • Recurrent NSCLC: Defined as the re-appearance of measurable disease, or the appearance of new measurable disease by RECIST Criteria after prior successful treatment or complete response.
  • Refractory NSCLC: Defined as achieving less than a complete response and having residual measurable disease by RECIST criteria after prior treatment with chemotherapy, targeted or small molecules, monoclonal antibodies or any combination of these.
  • Eastern Cooperative Oncology Group (ECOG)Performance Status ≤ 1.
  • Serum albumin ≥3.0 gm/dL.
  • Expected survival ≥4 months.
  • Adequate organ function including:

    1. Marrow: Hemoglobin ≥10.0 dm/dL, absolute granulocyte count (AGC)≥1,000/mm^3, platelets ≥100,000/mm^3, absolute lymphocyte count ≥1000/mm^3.
    2. Hepatic: Serum total bilirubin ≤1.5 x upper limit of normal (ULN) with the exception of <2.9 mg/dL for patients with Gilbert's disease, alanine aminotransferase (ALT/SGPT) and aspartate aminotransferase (AST/SGOT) ≤2.5 x ULN.
    3. Renal: Serum creatinine (sCr) ≤1.5 x upper limit of normal, or creatinine clearance (Ccr) ≥50 mL/min.
  • Measurable disease as defined by RECIST Criteria.
  • Prior therapy for NSCLC that may include surgery, radiation therapy, immunotherapy and/or ≤ 2 prior chemotherapy regimens (such as neoadjuvant/adjuvant treatment), however only 1 chemotherapy regimen in the metastatic setting is allowed.
  • Treatment with a single course of gefitinib(Iressa®) or erlotinib (Tarceva®), or other small molecule or targeted therapies, or monoclonal antibody therapy (excluding docetaxel) will be considered and count as prior chemotherapy.
  • Patients receiving preoperative (Neoadjuvant) and postoperative adjuvant chemotherapy (within 12 weeks of surgery) with the same agent(s) will be considered to have received a single chemotherapy regimen.
  • Patients must be ≥ 4 weeks since major surgery, chemotherapy (6-weeks if they were treated with a nitrosourea or mitomycin) or biotherapy/target therapies and ≥ 2 weeks since radiotherapy.
  • Patients must have the ability to understand the study, its risks, side effects, potential benefits and be able to give written informed consent to participate. Patients may not be consented by a durable power of attorney (DPA).
  • Male and female subjects of child producing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental drug and for one month after the last immunization.

Exclusion Criteria:

  • Age < 18-years-old.
  • Active central nervous system (CNS) disease, metastases or carcinomatous meningitis. Patients with CNS metastases must be at least 2 weeks status post prior therapy to the brain and be off all steroids without progressing CNS disease.
  • Hypercalcemia >2.9 mmol/L, unresponsive to standard therapy (e.g., I.V. hydration, diuretics, calcitonin and/or bisphosphate therapy).
  • Pregnant or nursing women due to the unknown effects of immunization on the developing fetus or newborn infant.
  • Other malignancy within three years, unless the probability of recurrence is <5%. Patients curatively treated for squamous cell carcinoma and basal cell carcinoma of the skin and carcinoma in situ of the uterine cervix (CIN) or patients with a history of malignant tumor in the past that have been disease free for at least five years are also eligible for this study.
  • History of organ transplant, or current active immunosuppressive therapy (such as cyclosporine, tacrolimus, etc.).
  • Subjects taking systemic corticosteroid therapy for any reason including replacement therapy for hypoadrenalism, are not eligible. Subjects receiving inhaled or topical corticosteroids are eligible. Decadron treatment with docetaxel is acceptable.
  • Significant or uncontrolled congestive heart failure (CHF), myocardial infarction, significant ventricular arrhythmias within the last six months or significant pulmonary dysfunction.
  • Active infection or antibiotics within 48 hours prior to study enrollment, including unexplained fever (temp > 38.1°C) if deemed clinically significant by the treating physician.
  • Autoimmune disease (e.g., systemic lupus erythematosis (SLE), rheumatoid arthritis (RA), etc.). Patients with a remote history of asthma or mild active asthma are eligible.
  • Other serious medical conditions that may be expected to limit life expectancy to less than 2 years (e.g., liver cirrhosis).
  • Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc).
  • A known allergy to any component of the HyperAcute®-Lung immunotherapy or cell lines from which it is derived.
  • Patients having undergone splenectomy.
  • Known HIV positive.
  • Subjects who received any prior treatment with docetaxel are excluded. Subjects who have received gemcitabine in first line therapy but do not have squamous cell carcinoma, will be eligible as they can receive pemetrexed for the salvage regimen.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01774578

Locations
United States, California
Redwood Regional Medical Group Recruiting
Santa Rosa, California, United States, 95403
Contact: Kim Young, RN, CCRC    707-521-3814    kyoung@rrmg.com   
Principal Investigator: Ian Anderson, MD         
United States, Connecticut
Stamford Hospital Recruiting
Stamford, Connecticut, United States, 06902
Contact: Ed Hatton    203-276-8447    EHatton@stamhealth.org   
Principal Investigator: Salvatore Del Prete, MD         
United States, Florida
University of Florida Recruiting
Gainesville, Florida, United States, 32610
Contact: Alison Ivey, RN, BSN, OCN, CCRP    352.265.0680 ext 88411    aivey@ufl.edu   
Principal Investigator: Frederic Kaye, MD         
United States, Illinois
Illinois Cancer Specialists Recruiting
Arlington Heights, Illinois, United States, 60005
Contact: Heather Lee    847-259-0624    Heather.lee@usoncology.com   
Principal Investigator: Rich Siegel, MD         
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Hala Simm    312-695-1365    h-simm@northwestern.edu   
Principal Investigator: Jyoti Patel, MD         
United States, Indiana
Deaconess Clinic Recruiting
Evansville, Indiana, United States, 47713
Contact: Christina Burkes    812-426-9334    Christina.burkes@deaconess.com   
Principal Investigator: Maqbool Ahmed, MD         
Indiana University Health Goshen Center for Cancer Care Recruiting
Goshen, Indiana, United States, 46526
Contact: Vanessa DePue    574-364-2649    vdepue@iuhealth.org   
Principal Investigator: Ebenezer Kio, MD         
Indiana University Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Matt Burns    317-278-8247    matburns@iupui.edu   
Principal Investigator: Shadia Jalal, MD         
United States, Kansas
University of Kansas Cancer Center Recruiting
Fairway, Kansas, United States, 66205
Contact: Julie Collins    913-945-6594    jcollins4@kumc.edu   
Principal Investigator: Chao Huang, MD         
United States, Mississippi
North Mississippi Hematology and Oncology Associates at BridgePoint Recruiting
Tupelo, Mississippi, United States, 38801
Contact: Marthe Thomas, RN, BSN, CCRC       mthomas_nmho@dixie-net.com   
Principal Investigator: Christopher Croot, MD         
United States, Missouri
Washington University School of Medicine Recruiting
St. Louis, Missouri, United States, 63110
Contact: Melissa K Schultz    314-362-4140    MSCHULTZ@DOM.wustl.edu   
Principal Investigator: Ramaswamy Govindan, MD         
United States, Nebraska
University of Nebraska Medical Center Recruiting
Omaha, Nebraska, United States, 68198
Contact: Jolene M. Tijerina, RN,BSN    402-559-8711    jolene.tijerina@unmc.edu   
Principal Investigator: Apar Kishor P. Ganti, MD         
United States, New York
Richmond University Medical Center Recruiting
Staten Island, New York, United States, 10310
Contact: Marion Smith, RN, MS, OCN    718-818-1025    marismith@rumcsi.org   
Principal Investigator: Thomas J Forlenza, MD         
United States, Ohio
Gabrail Cancer Center Recruiting
Canton, Ohio, United States, 44718
Contact: Carrie Smith    330-492-3345    csmith@gabrailcancercenter.com   
Principal Investigator: Nashat Gabrail, MD         
University of Cincinnati Recruiting
Cincinnati, Ohio, United States, 45219
Contact: U.C. Cancer Institute    513-584-7698      
Principal Investigator: John C Morris, MD         
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
Contact: Cleveland Clinic Taussig Cancer Institute    866-223-8100    cancercenterresearch@ccf.org   
Principal Investigator: Nathan Pennell, MD         
United States, Tennessee
University of Tennessee Medical Center Recruiting
Knoxville, Tennessee, United States, 37920
Contact: Randi R. Ray, RN, BSN, OCN    865-305-9773    RRRay@mc.utmck.edu   
Principal Investigator: Janakiraman Subramanian, MD         
United States, Virginia
Lynchburg Hematology Oncology Clinic Recruiting
Lynchburg, Virginia, United States, 24501
Contact: Donna Washburn    434-200-1495    Donna.Washburn@Centrahealth.com   
Principal Investigator: Dwight Oldham, MD         
United States, Wisconsin
Vince Lombardi Cancer Clinic Recruiting
Green Bay, Wisconsin, United States, 54311
Contact: Kate Newbanks    920-288-4115    kate.newbanks@aurora.org   
Principal Investigator: Dhimant Patel, MD         
University of Wisconsin Recruiting
Madison, Wisconsin, United States, 53792
Contact: Danae Walters    608-262-5706    dmwalters@uwcarbone.wisc.edu   
Principal Investigator: Toby Campbell, MD         
Sponsors and Collaborators
NewLink Genetics Corporation
Investigators
Study Director: Nicholas N Vahanian, MD NewLink Genetics Corporation
  More Information

No publications provided

Responsible Party: NewLink Genetics Corporation
ClinicalTrials.gov Identifier: NCT01774578     History of Changes
Other Study ID Numbers: NLG0301, 1209-1184
Study First Received: January 7, 2013
Last Updated: July 1, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by NewLink Genetics Corporation:
Non-small Cell Lung Cancer
Vaccine Therapy
Immunotherapy
Second line therapy
Progressive
Relapsed

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Gemcitabine
Pemetrexed
Docetaxel
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Folic Acid Antagonists

ClinicalTrials.gov processed this record on August 26, 2014